Phyllis Gimotty

8PUBLICATIONS
100CO-AUTHORS
Molecular targetsPredictive and prognostic markersGene and molecular therapyElectrochemical energy storage and conversionApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Nov 04, 2026
Olaparib plus tremelimumab in women with recurrent ovarian cancer and a germline BRCA1 or BRCA2 mutation: a phase I/II study.

|Jan 28, 2026
Improving a Plasma Biomarker Panel for Early Detection of Pancreatic Ductal Adenocarcinoma with Aminopeptidase N (ANPEP) and Polymeric Immunoglobulin Receptor (PIGR).

Brianna M Krusen, Phyllis A Gimotty, Greg Donahue

|Jan 31, 2025
Evolving racial/ethnic disparities in AML survival in the novel therapy era.

Xin Wang, Phyllis A Gimotty, Andrew H Matthews

|Jan 15, 2025
Engineered extracellular vesicles with DR5 agonistic scFvs simultaneously target tumor and immunosuppressive stromal cells.

Yeye Guo, Huaishan Wang, Shujing Liu

|Oct 24, 2024
Dietary pro-oxidant therapy by a vitamin K precursor targets PI 3-kinase VPS34 function.

Manojit M Swamynathan, Shan Kuang, Kaitlin E Watrud

|Sep 09, 2024
Tumor-Infiltrating Lymphocytes in Necrotic Tumors after Melanoma Neoadjuvant Anti-PD-1 Therapy Correlate with Pathologic Response and Recurrence-Free Survival.

Kevin L Ma, Tara C Mitchell, Meaghan Dougher

Pageof 2

Frequent Collaborators

3 joint publications

Alexander C Huang

2 joint publications

Xiaowei Xu

2 joint publications

Ravi K Amaravadi

2 joint publications

Meenhard Herlyn